Systemic activity and mortality in primary Sjögren syndrome: Predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients

Annals of the Rheumatic Diseases

Volumn 75, Issue 2, 2016, Pages 348-355

  Brito Zeron P ^a   Kostov, B ^a,b   Solans, R ^c   Fraile, G ^d   Suarez Cuervo C ^e   Casanovas, A ^f   Rascon F J ^g   Qanneta, R ^h   Perez Alvarez R ⁱ   Ripoll, M ^j   Akasbi, M ^k   Pinilla, B ^l   Bosch, J A ^c   Nava Mateos, J ^d   Diaz Lopez B ^e   Morera Morales, M L ^f   Gheitasi, H ^a   Retamozo, S ^a   Ramos Casals, M ^a   Bove A ^a   Ramentol, M ^c   Perez Diaz B ^e   Suarez Cuervo, C ^e   Caravia Duran, D ^e   Junco Russeau, T E ^f   Pallares L ^g   Perez de Lis, M ⁱ   Lopez Berastegui, O ^l   Garcia Sanchez I ^k   Camps, M T ^m   Ayala, M M ^m   Sopena B ⁿ   Maure, B ⁿ   Callejas, J L ^o   Fonseca, E ^p   Canora, J ^q   Nadal, E ^r   Merino Palacios, C ^r   De La Red, G ^s   Chamorro, A J ^t   Fernandez Regal I ^t   Jimenez Heredia I ^u   Mendizabal, A ^u   Adrianov, B ^b   Siso Almirall A ^b   more..

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^f HOSPITAL DE SABADELL   (Spain)

^g HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^h HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

ⁱ HOSPITAL DO MEIXOEIRO   (Spain)

^j HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^k HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^l HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^m HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

ⁿ Hospital Universitario   (Spain)

^o HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^p HOSPITAL DE CABUEÑES   (Spain)

^q HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^r Hospital La Ribera   (Spain)

^s Hospital Espíritu Santo   (Spain)

^t Nephrology Department   (Spain)

^u HOSPITAL DE MANISES   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CRYOGLOBULIN; LA ANTIBODY; ANTINUCLEAR ANTIBODY; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; DEATH; DISEASE ACTIVITY; EULAR SS DISEASE ACTIVITY INDEX; FEMALE; GENDER; HUMAN; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MORTALITY; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; SJOEGREN SYNDROME; SPANIARD; STANDARDIZED MORTALITY RATIO; SURVIVAL RATE; BLOOD; EUROPE; MIDDLE AGED; ONSET AGE; PARAPROTEINEMIA; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; SEVERITY OF ILLNESS INDEX; TIME FACTOR; VERY ELDERLY;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; BIOMARKERS; COMPLEMENT C3; COMPLEMENT C4; CRYOGLOBULINS; EUROPE; FEMALE; HUMANS; LYMPHOPENIA; MALE; MIDDLE AGED; PARAPROTEINEMIAS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME; TIME FACTORS;

EID: 84954357751     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206418     Document Type: Article

References (30)

1. Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, et al. Primary Sjogren syndrome. BMJ 2012;344:e3821.
2. Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjögren syndrome: a systematic review. JAMA 2010;304:452-60.
3. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 2002;46:741-7.
4. Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study. Arthritis Rheum 2004;50:1262-9.
5. Brito-Zerón P, Ramos-Casals M, Bove A, et al. Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors. Rheumatology (Oxford) 2007;46:1359-62.
6. Baldini C, Pepe P, Quartuccio L, et al. Primary Sjogren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology (Oxford) 2014;53:839-44.
7. Seror R, Theander E, Bootsma H, et al. Outcome measures for primary Sjögren's syndrome: a comprehensive review. J Autoimmun 2014;51:51-6.
8. Ramos-Casals M, Brito-Zerón P, Solans R, et al; SS Study Group; Autoimmune Diseases Study Group (GEAS) of the Spanish Society of Internal Medicine (SEMI). Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology (Oxford) 2014;53:321-31.
9. Seror R, Gottenberg JE, Devauchelle-Pensec V, et al. European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients. Arthritis Care Res (Hoboken) 2013;65:1358-64.
10. Vitali C, Bombardieri S, Jonsson R, et al; European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
11. Seror R, Theander E, Brun JG, et al; on behalf of the EULAR Sjögren's Task Force. Validation of EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 2015;74:859-66.
12. Ramos-Casals M, la Civita L, de Vita S, et al; SS-HCV Study Group. Characterization of B cell lymphoma in patients with Sjögren's syndrome and hepatitis C virus infection. Arthritis Rheum 2007;57:161-70.
13. Pérez-De-Lis M, Akasbi M, Sisó A, et al. Cardiovascular risk factors in primary Sjögren's syndrome: a case-control study in 624 patients. Lupus 2010;19: 941-8.
14. Instituto Nacional de Estadi´stica. Tasas de Mortalidad segu´n sexo y edad. http://www.ine.es/jaxi/tabla.do?per=12&type=db&divi=IDB&idtab=35 (accessed 17 July 2014).
15. Seror R, Gottenberg JE, Bootsma H, et al. Defining disease activity sates and minimal clinically important improvement with the EULAR primary Sjögren's syndrome disease activity index (ESSDAI). Ann Rheum Dis 2014;73(Suppl 2):75.
16. Skopouli FN, Dafni U, Ioannidis JP, et al. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum 2000;29: 296-304.
17. Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978;89:888-92.
18. Kruize AA, Hené RJ, van der Heide A, et al. Long-term followup of patients with Sjögren's syndrome. Arthritis Rheum 1996;39:297-303.
19. Davidson BK, Kelly CA, Griffiths ID. Primary Sjögren's syndrome in the North East of England: a long-term follow-up study. Rheumatology (Oxford) 1999;38:245-3.
20. Martens PB, Pillemer SR, Jacobsson LT, et al. Survivorship in a population based cohort of patients with Sjögren's syndrome, 1976-1992. J Rheumatol 1999;26:1296-300.
21. Pertovaara M, Pukkala E, Laippala P, et al. A longitudinal cohort study of Finnish patients with primary Sjögren's syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis 2001;60:467-2.
22. Alamanos Y, Tsifetaki N, Voulgari PV, et al. Epidemiology of primary Sjögren's syndrome in north-west Greece, 1982-2003. Rheumatology (Oxford) 2006;45:187-91.
23. Palm O, Garen T, Berge Enger T, et al. Clinical pulmonary involvement in primary Sjogren's syndrome: prevalence, quality of life and mortality-a retrospective study based on registry data. Rheumatology (Oxford) 2013;52:173-9.
24. Nannini C, Jebakumar AJ, Crowson CS, et al. Primary Sjogren's syndrome 1976-2005 and associated interstitial lung disease: a population-based study of incidence and mortality. BMJ Open 2013;3:e003569.
25. Goules AV, Tatouli IP, Moutsopoulos HM, et al. Clinically significant renal involvement in primary Sjögren's syndrome: clinical presentation and outcome. Arthritis Rheum 2013;65:2945-53.
26. Jonsson R, Theander E, Sjöström B, et al. Autoantibodies present before symptom onset in primary Sjögren syndrome. JAMA 2013;310:1854-5.
27. Brito-Zeron P, Ramos-Casals M. Advances in the understanding and treatment of systemic complications in Sjögren syndrome. Curr Opin Rheumatol 2014;26:520-7.
28. Juarez M, Toms TE, de Pablo P, et al; UK Primary Sjögren's Syndrome Registry. Cardiovascular risk factors in women with primary Sjögren's syndrome: United Kingdom primary Sjögren's syndrome registry results. Arthritis Care Res (Hoboken) 2014;66:757-64.
29. Bartels CM, Buhr KA, Goldberg JW, et al. Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol 2014;41:680-7.
30. Kerola AM, Kauppi MJ, Kerola T, et al. How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear? Ann Rheum Dis 2012;71:1606-15.